Our Core Values
Quality is at the heart of what we do. We are dedicated to maintaining the highest standards of manufacturing and producing high-quality medicines. At a profit if we can, but always high quality.
We hold ourselves to a high standard of accountability and integrity, being a trustworthy partner to our EU and Chinese customers and working openly with the regulatory authorities. We are honest with ourselves and others about our mistakes and deficiencies.
We aim to provide excellent service to our customers and partners. Our business is about supply and we should deliver our products and services in full, on time, every time. Where we can’t do something, we inform our customers as early as possible and look for a solution.
We have a responsibility to patients to maintain supply of their medicines. We have a responsibility to our employees to provide job security, fulfilment, opportunities for progression and a safe and pleasant working environment. We have a responsibility to our shareholders to protect their investment and provide a return. We have a responsibility towards the environment and to minimise our impact.
We prioritise good decision-making and seek to overcome challenges with new ideas. Although we are a generic company, we seek to innovate to improve our products and services. We work to get the maximum results from the resources we have.
We always remember that the products we make heal the sick. Compassion for the patients we serve must be a foundation for all our actions. We try to understand the perspectives of the customers we serve and the employees with whom we work.
Our goal is to become the leading independent Chinese medicine supplier. We will expand the range of dosage forms we supply and the markets we serve. We are not afraid to try new technologies and develop new products.
We strive to develop an open and just company culture, valuing communication at all levels. We recognise the cultural differences between China and the countries where our customers operate and our patients reside and we are open to different ways of doing things.
Why become our partner?
Since our establishment, we have completed site transfers of over 50 products and supply a billion doses a year to European customers. We have successfully developed dossiers for Europe resulting in granted marketing authorisations.
We have recently expanded our capability to develop products to Chinese standards also and can produce dossiers that meet both European and Chinese requirements. Together with our associated company Velocyte, we can also offer bio-equivalence studies in China to seamlessly complete the clinical part of the development.
Huayi is committed to upgrading and developing our services. We aim to increase our current manufacturing capacity from 3 billion units to 5 billion units to satisfy demand. We are building new facilities for high-potency and oral liquid manufacturing scheduled for production in 2020.
Analytical method development
Bio-equivalence studies in China through our partner company
Contract manufacturing and commercial supply
Full regulatory compliance (toxicological assessment, serialisation etc.)
Research & Development
We are experienced in technology transfers and scale-up process for commercial production. Having transferred over 50 products for our customers and registering almost 100 strengths to date, we are prepared to take on new challenges in pharmaceutical development with our experienced team from Huayi China-Europe Pharmaceutical Research Institute.Read More
01 / 04
Huayi’s QA team is committed to ensuring your project adheres to EU cGMP standards at every step of production from development to commercial manufacture. We will work hard to ensure that your project will be completed on time to the highest quality and stay focused and communicative throughout the process.Read More
02 / 04
In 2018, our contract manufacturing output reached 1.6 billion units. Huayi manufactures solid oral dosage forms including film-coated, sugar-coated, enteric-coated, effervescent, soluble, chewable and buccal tablets as well as capsules. Our high-potency and liquid preparation facilities will be ready in 2020.Read More
03 / 04
We offer bioequivalence studies for your next project in China. Through our partners Weida Clinical Research and Velocyte Analytical Technology, we can conduct clinical trials, biological sample testing, dissolution profiling and stability studies. We can then scale-up from the test batch to commercial production.Read More
04 / 04